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CravingOral naltrexone reduces heavy drinking, but is less consistent as an abstinence promoter, whereas once-monthly
extended-release naltrexone (XR-NTX) also maintains abstinence. The present study sought to determine if alco-
hol cue reactivity is attenuated by XR-NTX. Twenty-eight detoxiﬁed alcohol-dependent adultmale and female vol-
unteers received a single i.m. injection of either XR-NTX or placebo under double-blind conditions. An fMRI/cue
reactivity procedure was conducted immediately before and two weeks after injection. At baseline, alcohol-
related visual and olfactory cues elicited signiﬁcant increases in orbital and cingulate gyri, inferior frontal andmid-
dle frontal gyri. Subsequently, brain activation was signiﬁcantly altered in XR-NTX-treated individuals. These af-
fected brain regions are associated with the integration of emotion, cognition, reward, punishment, and
learning/memory, suggesting that XR-NTX attenuates the salience of alcohol-related cues. Such an effect on
brain function may interrupt the processes associated with “slips” and relapse, which may account for XR-NTX's
ability to maintain abstinence.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Oral naltrexone has a long record of safe clinical use in the treatment
of opioid addiction and alcohol dependence. This drug exhibits a low
level of toxicity, and in clinical use, adverse events (AEs) are generally
mild ormoderate and reversible (McEvoy, 1999). In addition,when com-
bined with various treatment programs, naltrexone has been found to
decrease drinking rates, prolong abstinence, and hinder relapse to un-
controlled drinking among abstinent alcoholics who sampled alcohol
during treatment (Anton, 1999; Kranzler, 2000; O'Malley et al., 1992;
Volpicelli et al., 1992). However, shortcomings related to compliance
and adverse effects limit the utility of oral naltrexone for the treatment
of alcohol dependence. Meta-analyses of placebo-controlled trials of
oral naltrexone (n = 19), have failed to ﬁnd signiﬁcant beneﬁt for
complete abstinence rates during treatment (Bouza et al., 2004;
Srisurapanont and Jarusuraisin, 2005) and somehave raised the possibil-
ity that naltrexone's beneﬁt may even require “sampling” alcohol in
order to facilitate extinction (Sinclair, 2001).
In April 2006, Vivitrol® (naltrexone for extended-release inject-
able suspension or XR-NTX) was approved in the United States for
the treatment of alcohol dependence in subjects who are able to ab-
stain from alcohol in an outpatient setting prior to initiation ofng Center, Belmont MA, 02478,
kas).
NC-ND license.treatment (Gastfriend, 2011). This extended-release, microsphere for-
mulation of naltrexone is administered by intramuscular (IM) gluteal
injection every 4 weeks and in abstinent alcohol dependent adults re-
ceiving psychosocial therapy, has demonstrated efﬁcacy in prolonging
initial abstinence andmaintaining total (i.e., 6-month) abstinence com-
pared to placebo— i.e., in the absence of “sampling” alcohol (O'Malley et
al., 2007). XR-NTX is generally well tolerated and only infrequent
treatment-related AEs have been reported (nausea, injection site reac-
tion and headache). This raises the question as to what is the mecha-
nism by which XR-NTX might exert its clinical effect on abstinence.
It has been suggested that exposure to cues may lead to the acti-
vation of certain “automatic” cognitive functions, resulting in repet-
itive, unwanted thoughts about alcohol. These automatic thoughts
are the cognitive equivalent of unconscious craving (Anton, 2000).
Craving also may arise in part from persistent nervous system
changes (i.e., neuroadaptation) that leave the alcoholic's brain vul-
nerable to relapse drinking (Koob, 2000). These changes persist in
the absence of alcohol, and may result in conscious or unconscious
physical and mental distress. This phenomenon could account for the
craving alcoholics experience soon after the cessation of drinking,
whichmakes them vulnerable to relapse for a protracted period of time.
A comprehensive understanding of craving requires the integra-
tion of unconscious and cognitive mechanisms (Rohsenow and
Monti, 1999). Among the concepts of craving discussed here, both
the social learning and cognitive processing models implicate cogni-
tive learning in the development of harmful drinking patterns and
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holism therapy. Both of these models are also consistent with the in-
volvement of other causal mechanisms, including reinforcement and
other unconscious processes (Anton, 1999; Tiffany, 1999).
Craving studies based on a wide-range of imaging technologies of
humans have identiﬁed speciﬁc regional changes in brain cell activity
in response to alcohol-related cues (Anton et al., 2001; George et al.,
2001; Hommer, 1999). Because these ﬁndings alone do not prove
that the observed brain changes actually cause the subjective sensa-
tion of craving (Sayette et al., 2000), a more precise method to mon-
itor how these urges affect the brain and is needed, and fMRI is well
suited to provide this metric.
Echo-planar fMRI increases the temporal resolution for acquiring
functional neuroanatomical images beyond what has been available
with radionuclide scanning. Compared to other imaging modalities,
fMRI is more likely to identify transient drug-induced changes in re-
gional cerebral blood ﬂow (CBF) or metabolism. Spatial resolution is
excellent with fMRI, which contains connectivity and functional in-
formation in the same image.
The use of fMRI to track the effects of alcohol-related stimuli on cen-
tral nervous system function has been well-validated. Braus et al.
(2001) demonstrated that the ventral striatum (VS) was activated by
presenting recently detoxiﬁed alcoholics with alcohol-associated visual
cues. This research team later showed that this cue activation in the stri-
atum and medial prefrontal cortex was associated with subsequent re-
lapse in abstinent alcoholics (Grusser et al., 2004), while Kareken et al.
(2004) demonstrated that olfactory cues activated nucleus accumbens
and ventral tegmental areas in high risk drinkers. Finally, Myrick et al.
(2008) demonstrated that oral naltrexone alone, and in combination
with ondansetron, decreased alcohol cue-related activation of the VS
in alcohol-dependent individuals. Only visual cues were studied and
the analyses were conﬁned to the VS.
Here, we tested the ability of a single i.m. injection of XR-NTX to
alter whole-brain activation patterns (as measured by BOLD fMRI) as-
sociated with the delivery of alcohol-related visual and olfactory cues
in individuals who are being treated for their alcohol dependence.Methods
General
The present study was a double-blind, placebo-controlled between-
subject design to test whether XR-NTX attenuates brain responses to
alcohol-related olfactory and visual cues in treatment-seeking alcohol-
dependent individuals. The protocol was reviewed and approved by
the McLean Hospital Institutional Review Board (IRB); all participants
read and signed an informed consent form before receiving a physical
exam and psychiatric screen to participate in the study. A total of 31
adult (age 46.6 ± 9.2 years, mean ± S.D.) male (N = 21) and female
(N = 10), recently detoxiﬁed individuals passed the screening protocol
and were randomized to the protocol. Medication randomization was
stratiﬁed by sex and age. A total of 24were Caucasian and 7were African
American. The participants reported drinking on average a total of
82.8 ± 10.8 drinks per week during their most recent drinking period
prior to their detoxiﬁcation. A separate drug use questionnaire was
used to collect information of drug and alcohol use histories and
patterns. Mean age of initiation of heavy drinking was reported to be
24.7 ± 10.8 years (range 16–55). Nineteen did not smoke tobacco
and those who did smoke reported smoking 17.3 ± 7.4 cigarettes per
day. Thirteen reported using no other drug of abuse, while the remain-
der reported occasional (or past) use of cannabis (N = 11), cocaine
(N = 10) and opioids (N = 1); some participants reported using
more than one drug. All received a diagnosis of alcohol dependence
via DSM-IV criteria and none received a diagnosis of dependence on
any other drug including opiates, stimulants or sedative/hypnotics.Medication treatment
The fMRI results are based on 28 individuals who successfully
completed both fMRI sessions, yielding valid pre and post treatment
data. Of these 28 participants, a total of 15 were randomized to re-
ceive XR-NTX (380 mg, i.m.), while 13 received placebo injection.
XR-NTX is a microsphere formulation of naltrexone for suspension
that is available in dose strength of 380 mg naltrexone per vial. The
XR-NTX microspheres contain approximately 34% (w/w) naltrexone
incorporated into a 75:25 matrix of poly (D,L-lactide co-glycolide)
polymer (PLG). PLG is a common, biodegradable medical polymer
having a history of safe human usage in sutures, bone plates and
slow-release pharmaceuticals (e.g., Risperdal Consta®, Zoladex®,
Lupron Depot®, Decapeptyl® SR and Sandostatin LAR®Depot). Placebo
for XR-NTX microspheres consists of a sterile, white, powder of 75:25
PLG.
Behavioral treatment
All participants attended weekly relapse prevention counseling ses-
sions conducted by a trained clinician—this was done to ensure that
placebo-treated participants received some form of therapy. The ses-
sions lasted approximately 60 min. A cognitive strategy was used
with an emphasis on self-management and coping skills. The goal of
the treatment was to develop coping skills that would help the partici-
pants maintain abstinence from alcohol. A Clinical Global Impressions
(CGI)was also performed at each study visit to assess therapeutic effect.
The day after the fMRI scan (Day 1), subjects were contacted via
telephone by site personnel to offer support following cue exposure.
In addition, weekly visits were conducted for the ﬁrst month after dos-
ing and included the following assessments: laboratory tests, adverse
events (AEs), vital signs, questionnaire responses and urine toxicology.
Pregnancy tests were conducted as applicable on a monthly basis.
Experimental procedure
Data were acquired using a Siemens 3 T Trio whole body scanner
with a transmit-receive quadrature birdcage head coil. A baseline
fMRI scan/cue reactivity assessment was conducted at Visit 2 (Day 0)
prior to randomization. Subject responses were collected via a keypad
device in response to a computerized visual analog questionnaire.
Visual stimuli were delivered using a projector, translucent screen,
and mirrors; a custom-built olfactometer based on Lowen and
Lukas (2006) provided olfactory stimuli. See Fig. 1 for a layout of
the room conﬁguration. The participants were instructed to use a
MR compatible, ﬁber optic response pad (FORP, Current Designs,
Inc., Philadelphia, PA) to move the cursor on the screen. An identical
procedure was performed two weeks later.
Olfactory/visual cues
The MR-compatible olfactometer device (Lowen and Lukas, 2006)
delivered one of the three odorants [alcohol, phenyl ethyl alcohol
(rose scent) and humidiﬁed air (no odor)] automatically via comput-
er control through a disposable nasal cannula. The three odorant
streams converged near the subject to minimize delay due to dead
space. Participants were exposed to their preferred brand of alcohol.
For those who preferred beer, a thin layer of canola oil (1 mL) was
ﬂoated on this odorant to retard foaming. Pictures of alcohol- and
non alcohol-related images were presented to the participants via
the translucent screen. The alcohol-related images depicted various
types of beer, wine and distilled spirits in standard glasses and/or bot-
tles while the non-alcohol images were photos of water, milk and tea
in their various containers. Fig. 2 depicts the experimental procedure.
All participants viewed the same series of images, regardless of their
preferred alcoholic beverage.
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Fig. 1. Bird's eye view of the 3 T magnet scanner suite. Visual stimuli and VAS scales are projected onto a translucent screen that the participant can see with the aid of a small mirror
that is ﬁxed at a 45° angle. Participants' score responses using the FORP device. An olfactometer device is used to deliver olfactory cues. The air supply and switching mechanisms
are located outside of the imaging suite, but the odorant bottles are located just inside of the bore about 1.5 m from the participant's head.
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Functional scanning comprised a single, 28-min BOLD scan, divided
into 1-min blocks. Each block began with two Likert questions (“Want
to drink alcohol” and “Want to avoid drinking alcohol”), at 6 s each.
Each question began with the response indicator blank; the ﬁrst keyFig. 2. Experimental protocol—cue presentation during fMRI recording. Each minute of
non-alcoholic, and one odor – either rose or alcohol. Therefore, there were 4 conditions: alco
out alcohol odors. Two VAS questions were asked at the beginning of each sequence: “Want t
question. Air (pumped through water without any odor) ﬂowed while they were answering
tions, no other response was required. The order of presenting non-alcohol versus alcohol-r
images are presented ﬁrst (only a sample of the images is presented) and the rose odor wa
with the odors reversed.press made the indicator appear in the middle of the scale. This
provided an indicator for a lack of response. Subjects were able to
complete these questions within the time allotted. A ﬁnal question
pair was presented after the end of the last block. Pictures were
presented during the remaining 48 s of the block consisting of eitherthe scanning sequence was composed of one set of pictures – either alcoholic or
hol pictures with and without alcohol odors, and non-alcoholic pictures with and with-
o drink alcohol”, and “Want to avoid drinking alcohol?” Subjects had 6 s to answer each
these questions and air again after the odor was turned off. After answering the ques-
elated images was counterbalanced—in this example of two sequences the non-alcohol
s presented ﬁrst followed by the alcohol odor; two additional sequences are presented
Table 1
Demographic proﬁle of alcohol-dependent individuals who received one injection of
either XR-NTX or placebo. T-test for continuous variables, Chi-squared for discrete vari-
ables, both two-tailed.
Demographics XR-NTX Placebo T-test
Mean ± sd (N = 15) (N = 13) p value
Age (yrs) 49.93 ± 6.22 46.54 ± 8.52 p = 0.235
Males # (%) 11 (73) 10 (77)
Caucasian # (%) 12 (80) 10 (77)
Education (years) 14.43 ± 1.90 14.00 ± 1.78 p = 0.541
Height (cm) 173.06 ± 11.59 174.09 ± 8.14 p = 0.791
Weight (kg) 88.18 ± 17.14 81.65 ± 16.27 p = 0.313
BMI (kg/m2) 29.31 ± 4.04 26.71 ± 3.44 p = 0.081
Age drink heavily (yrs) 27.36 ± 12.53 22.67 ± 8.99 p = 0.291
No. drinks/wk (most recent) 92.38 ± 67.17 75.03 ± 55.61 p = 0.468
Days sober @ baseline 42.40 ± 31.53 59.85 ± 65.14 p = 0.365
Placebo XR-NTX
0
1
2
3
4
5
6
7
Baseline
Post Treatment
Treatment
*
Subjective Report of 
“Want Alcohol”
Fig. 3. Peak reports of “Want Alcohol” during the fMRI session during which participants
were exposed to both olfactory and visual cues. * indicates signiﬁcant difference from
baseline.
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cohol or placebo, was turned on at the beginning of the picture presen-
tation, and turned off 24 s later (to prevent habituation effects). All four
odor/picture combinationswere presented in a counterbalanced design
identical for all subjects, with the same odor or picture type never
appearing more than two blocks in a row. Both immediately before
and immediately after the BOLD scan, subjects completed an AAAQ
(McEvoy et al., 2004) using a Likert scale. The scale started at “Not at
all” for all questions except for the “Aroused” question that began in
the middle. Subjects moved the indicator using the FORP device, and
had 10 s to respond to each of the 18 questions.
fMRI scanning
Scans were performed on a 3 T Siemens Trio MR imaging system
(Siemens AG, Erlangen, Germany). The BOLD scan was a gradient
echo EPI, TR/TE = 3000/30 ms, 224 × 224 mm FOV, 41 3.5-mm in-
terleaved axial slices starting from the spinal cord covering the entire
brain, no gap, AP readout, 64 × 64 pixel, full k-space acquisition, no
SENSE acceleration; pulse sequence-enhanced version of the Siemens
epibold, yielding isotropic 3.5 mm voxels. The BOLD scan comprised
567 acquired images, preceded by two additional images (6 s) to en-
sure steady-state magnetization. Other scans included a T1-weighted
matched-warped scan (Rohan et al., 2001), and a standard T1 weighted
MP-RAGE3D scan (FOV = 256 × 256 × 170 mm, 256 × 256 × 128).
fMRI analysis
With the exception of a few in-house programs, data processing was
performed using FSL Release 4.1.2 (FMRIB Analysis Group, Oxford Uni-
versity, UK, http://www.fmrib.ox.ac.uk/fsl/), speciﬁcally FEAT version
number 5.98, set to default values unless otherwise speciﬁed. An
in-house despiking ﬁlter was applied to all BOLD data ﬁrst. Subsequent
preprocessing steps were motion correction using mcﬂirt (Jenkinson et
al., 2002). If the maximum Euclidean deviation from this reference
exceeded 3.5 mm (the voxel dimension) for an image, that image was
effectively removed from analysis (see “Single-image regressors”,
below). If more than ten such images occurred in any scan, both scans
(all MRI data) for that subject were discarded. Slice timing correction
was performed and all non-brain voxels were removed. Spatial ﬁltering
was then performed, followed by global normalization and temporal
high-pass ﬁltering with a cutoff of 120 s. Regularized autocorrelation
functions were independently estimated for each voxel, using temporal
Tukey prewhitening (Woolrich et al., 2001). Regressors comprised the
following: one for each of the two picture types; one for each of the
two odor types, matching the odor response temporal proﬁle (a trape-
zoidal form deﬁned by convolving the 24-s odorant presentation time
with a rectangular pulse with duration equal to a typical breathing
cycle of ten breaths per minute); habituation terms for these four
regressors, generated by multiplying each regressor by a linear ramp
and then orthogonalizing this against the original regressor; an odor-
by-picture interaction term; six motion regressors; and single-image re-
gressors, one for each image for which the deviation exceeded 3.5 mm.
Each odor, picture and interaction regressor was subjected to a
linear ﬁlter modeling the hemodynamic response function, having a
gamma impulse response, width of 3 s, and mean lag of 6 s. These re-
gressors were further subjected to the same temporal ﬁlter that was
applied to the data. The results of this analysis were discarded except
for the residuals. A principal component analysis was performed on
the 5000 voxels in the residuals that had the largest variance
(Madsen and Lund, 2006). The ﬁrst eight components were retained
and used as additional nuisance regressors (without hemodynamic
or other temporal ﬁltering) in a new general linear model, using the
same pre-processed functional data. Contrasts examined were as fol-
lows: control odor minus alcohol odor, control pictures minus alcohol
pictures, the two corresponding habituation terms, and the interac-
tion, as well as the opposites (negatives) of these.Functional resultswere alignedwith thematched T1-weighted scan,
which was in turn aligned with the high-resolution MPRAGE scan and
then theMNI152 standard brain using FNIRT. Rendering of the function-
al results in MNI space was performed once, after concatenating the
three alignments into a single matrix. A summary of this registration
was monitored for each run of each subject; no runs were eliminated
due to registration failure. Contrasts were compared between the two
scan visits (pre- and post-administration) in a ﬁxed effects model.
These single-subject results were combined in a mixed effects model,
and group contrasts run for the differences between the two groups
(XR-NTX and placebo). All results were ﬁrst converted to Z-scores,
and thresholded to a signiﬁcance level of p b 0.01 (uncorrected).
Using Gaussian random ﬁeld theory, clusters were found that achieved
a cluster-wide signiﬁcance level of p b 0.05, FWE corrected for multiple
comparisons over the whole brain.Results
Demographics and Subjective reports of alcohol effects
The demographic proﬁle of the two treatment groups is shown in
Table 1. Participants were in their mid 40's to early 50's year of age
with similar levels of education, drinking history and number of
days sober before entering the study. There were no signiﬁcant differ-
ences between the two treatment groups among any of the measures
at the baseline phase of the study. While the duration of abstinence
was quite variable, the present study was not powered to test wheth-
er this factor contributes to the effects of XR-NTX on cue reactivity.
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Fig. 4. Time course of reports of “Want Alcohol” during the fMRI session, during which participants were exposed to both olfactory and visual cues.
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during the MRI procedure at both baseline and again two weeks after
XR-NTXor Placebo injection. During the scans, the participantswere ex-
posed to both olfactory and visual cues during a 28-min session while
they responded to a visual analog scale on how much they wanted
alcohol at that time. The results of a 2 × 2 ANOVA revealed that
XR-NTX caused a signiﬁcant reduction in reports of “want” alcohol
while placebo had no effect on desire for alcohol. The time course of
the changes in “want” alcohol during the second cue presentation/
fMRI session are shown in Fig. 4. Both placebo- and XR-NTX-treated in-
dividuals experienced an initial increase in reports of “want” as the ses-
sion started, but the XR-NTX treated group experienced a reduction inODORS
(deactivate)
ODORS
(activate)
PICTURES
(activate)
Fig. 5. Changes in BOLD signal activation in response to alcohol-related and non-alcohol re
alcohol > alcohol contrasts; middle row (odors-activation): alcohol > non alcohol odor
Z-score range for odors is 2.3–5.0 and Z-score range for pictures is 2.0–5.8.desire for alcohol about 8–10 min after session onset. Desire for alcohol
rose again toward the end of the session, but remained lower than that
reported by the placebo-treated group.
fMRI
The fMRI results are described in terms of baseline effects of the
cues, followed by the effect of treatment on the BOLD signal activation
pattern to these cues at week 2 after treatment. During baseline,
alcohol-related visual and olfactory cues elicited signiﬁcant changes
in multiple brain regions that were distinctly different from one
another (Fig. 5 and Table 2). Both BOLD signal deactivation andlated odors and pictures during the baseline scan. Top row (odors-deactivation): non
contrasts. Bottom row (pictures-activation): alcohol > non-alcohol picture contrasts.
Table 2
Standard space coordinates, cluster size and signiﬁcance of contrast to each condition.
Cluster Activation extrema (region) MNI x MNI y MNI z Extent (mm3) Z Other regions
Odor response-deactivation
(Fig. 5, top)
1 R. Lateral occipital cortex, inferior division 52 −66 0 181,168 5.04 R. Lateral occipital cortex, superior division
R. Frontal pole 4 64 −2 4.58 R. Precuneous cortex
R. Middle temporal gyrus, temporooccipital part 58 −52 8 4.52 R. Paracingulate gyrus
R. Cingulate gyrus, anterior division 6 12 42 4.43 L. Lateral occipital cortex, inferior division
R. Middle temporal gyrus, temporooccipital part 62 −58 10 4.38 L. Lateral occipital cortex, superior division
R. Precuneus cortex 4 −74 66 4.25 R. Cingulate gyrus, posterior division
2 R. Frontal pole 40 44 30 47,112 4.8 L. Precuneous cortex
R. Middle frontal gyrus 50 8 44 4.77 L. Paracingulate gyrus
R. Frontal pole 28 46 34 4.69 L. Cingulate gyrus, anterior division
R. Frontal pole 28 38 40 4.69 R. Inferior temporal gyrus, temporooccipital part
R. Superior frontal gyrus 28 6 58 4.58 L. Cingulate gyrus, posterior divisio
R. Frontal pole 42 38 32 4.44 R. Supramarginal gyrus, posterior division
3 L. Frontal pole −38 46 30 14,472 4.4 R. Angular gyrus
L. Frontal pole −32 52 30 4.28 R. Juxtapositional lobule cortex
L. Frontal pole −34 56 20 4.17 R. Supramarginal gyrus, anterior division
L. Middle frontal gyrus −42 34 36 4.11 R. Frontal medial cortex
L. Frontal pole −34 40 40 4.1 L. Lingual gyrus
L. Frontal pole −26 50 34 3.86 R. Lingual gyrus
4 L. Precentral gyrus −40 −2 56 6184 3.9 R. Postcentral gyrus
L. Precentral gyrus −36 −4 52 3.83 R. Superior parietal lobule
L. Superior frontal gyrus −22 4 66 3.8 R. Cuneal cortex
L. Postcentral gyrus −54 −10 30 3.76 R. Middle temporal gyrus, posterior division
L. Precentral gyrus −32 −8 46 3.73 L. Inferior temporal gyrus, temporooccipital part
L. Precentral gyrus −50 −8 28 3.55 R. Inferior frontal gyrus, pars triangularis
R. Temporal occipital fusiform cortex
R. Frontal orbital cortex
R. Superior temporal gyrus, posterior division
R. Inferior Frontal gyrus, pars opercularis
L. Frontal medial cortex
L. Intracalcarine cortex
R. Planum temporale
L. Middle temporal gyrus, temporooccipital part
R. Temporal pole
R. R. occipital pole
R. Subcallosal cortex
Odor response-activation
(Fig. 5, middle)
1 R. Lingual gyrus 28 −48 4 13,768 4.28 L. Hippocampus
− 32 −46 6 4.11
− −16 −40 14 3.88
L. White matter −38 −48 −4 3.75
L. White matter −20 −52 12 3.74
R. White matter 26 −50 18 3.71
2 L. White matter −24 −10 28 3256 3.58
L. White matter −24 8 28 3.44
L. White matter −26 −16 30 3.36
L. White matter −24 −4 28 3.2
L. White matter −36 −16 24 3.19
L. White matter −20 8 20 3.05
Picture response-activation
(Fig. 5, bottom)
1 L. Occipital pole −4 −94 −10 31,328 4.87 L. Occipital fusifrom gyrus
R. Occipital pole 20 −102 −6 4.85 R. Occipital fusifrom gyrus
R. Occipital pole 12 −96 2 4.81
R. Occipital pole 8 −92 0 4.79
R. Lingual gyrus 14 −88 −8 4.73
L. Lingual gyrus −8 −88 −8 4.72
XR-NTX effects on odor response-activation
(Fig. 6)
1 L. Precentral gyrus −54 −10 50 8256 3.55 R. Frontal orbital cortex
L. Postcentral gyrus −28 −32 56 3.45 L. Frontal pole
L. Postcentral gyrus −48 −18 46 3.45 R. Cingulate gyrus
L. Postcentral gyrus −28 −28 72 3.42 R. Angular gyrus
L. Precentral gyrus −42 −14 52 3.38 R. Supramarginal gyrus, posterior division
L. Postcentral gyrus −60 −18 42 3.23 R. Supramarginal gyrus, anterior division
2 L. Paracingulate gyrus −6 56 8 3224 3.26 L. Superior parietal lobule
R. Frontal pole 30 44 −10 3.25
R. Frontal pole 24 46 6 3.20
R. Frontal pole 30 60 6 3.17
R. Frontal pole 24 44 12 3.16
R. Paracingulate gyrus 10 44 16 3.05
(continued on next page)
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Table 2 (continued)
Cluster Activation extrema (region) MNI x MNI y MNI z Extent (mm3) Z Other regions
3 R. Anterior supramarginal gyrus 66 −28 34 3008 3.89
R. Anterior supramarginal gyrus 62 −28 32 3.86
R. Anterior supramarginal gyrus 56 −24 28 3.39
R. Anterior supramarginal gyrus 62 −34 44 3.38
R. Posterior superior temporal gyrus 66 −30 18 3.34
R. Parietal operculum cortex 66 −30 22 3.20
4 R. Precentral gyrus 26 −24 60 2936 3.64
R. Postcentral gyrus 34 −30 68 3.30
R. Precentral gyrus 28 −22 68 3.24
R. Precentral gyrus 30 −16 66 3.18
R. Postcentral gyrus 40 −24 54 3.15
R. Precentral gyrus 32 −24 64 3.12
XR-NTX effects on picture response-activation
(Fig. 7)
1 L. Frontal pole −50 42 12 5576 4.21 L. Frontal orbital cortex
L. Frontal pole −28 46 34 4.00 R. Paracingulate gyrus
L. Frontal pole −44 46 20 3.87 R. Cingulate gyrus
L. Inferior frontal gyrus, pars opercularis −58 18 28 3.78 L. Middle frontal gyrus
L. Frontal pole −34 52 22 3.63
L. Frontal pole −30 56 22 3.51
2 R. White matter 12 34 −8 5024 3.88
R. White matter 16 44 −8 3.88
L. White matter −16 38 −14 3.63
L. Subcallosal cortex −8 26 −14 3.62
L. Frontal medial cortex −2 46 −16 3.32
R. Frontal medial cortex 8 42 −14 3.27
XR-NTX effects on odor response-activation
(Fig. 6)
182 S.E. Lukas et al. / NeuroImage 78 (2013) 176–185activation were prominent after presentation of odor cues. Deacti-
vation was widespread among a number of prefrontal, cingulate,
and lateral occipital cortex while activation was greatest in limbic
regions and some white matter (Fig. 5, top and middle rows). As
expected, increased brain activation was observed primarily in visu-
al cortex in response to alcohol-related pictures (Fig. 5, bottom
row).
Two scans were performed: one at baseline and another two weeks
after a single i.m. injection of either XR-NTX (N = 15) or matched pla-
cebo (N = 13). Analysis of the BOLD signal changes during exposure to
both alcohol-related odors and pictures revealed a number of signiﬁ-
cant differences between the placebo and active XR-NTX groups,
when comparing the ﬁrst and second scanning visits. The most salient
differences were reductions in brain activation in the XR-NTX-treated
group compared to the placebo-treated group for both visual and ol-
factory cues. Decreases in the response to alcohol odors (Fig. 6) were
signiﬁcant at p b 0.000008 and involved primarily superior frontal
gyrus (self-awareness, coordination and sensory processing),
supramarginal gyrus (Brodman 40—reading), postcentral gyrus
(sensory), angular gyrus (Brodman 39—language, mathematics and
cognition). No brain regions showed signiﬁcant increases in re-
sponse to alcohol odor cues.
Decreases in responses to the alcohol-related picture cues (Fig. 7)
were signiﬁcant at p b 0.0006. Differences were most pronounced in
orbital gyri (integration of emotion, cognition, reward and punish-
ment), cingulate gyrus (emotion, learning/memory), inferior frontal
gyrus (speech), and middle frontal gyrus (face recognition, word
meaning). No brain regions showed signiﬁcant increases in response
to alcohol picture cues.
Discussion
While other laboratories have used brain imaging to demonstrate
that alcohol-related cues activate brain regions associated with re-
ward and that medications can attenuate that response, this is theﬁrst study to demonstrate that injectable naltrexone decreases
reactivity to both alcohol-related olfactory and visual cues in
alcohol-dependent persons undergoing treatment. Furthermore,
the olfactory cues were chosen on the basis of each individual's pref-
erence, making the cue exposure session even more salient to each
participant. In both paradigms, the cue response attenuation was
detected in the absence of alcohol administration itself, suggesting
a mechanism by which XR-NTX may exert its clinical effect of
prolonging initial abstinence and maintaining continued abstinence
over time.
The present study found that there are systematic brain activation/
deactivation patterns in response to both olfactory and visual alcohol
cues. Visual cues have been used previously in this population (Myrick
et al., 2008), but while imaging modalities such as EEG and event-
related potentials have been used to track olfactory cues (Lorig, 1994),
this is the ﬁrst study using fMRI to identify the areas that are affected
by olfactory stimuli in an alcohol-dependent population.
To understand craving, scientists must identify the brain mecha-
nisms that lead to urges. To account for all manifestations of craving,
both conscious and unconscious processes must be taken into ac-
count (Anton, 2000). Many researchers and clinicians consider crav-
ing an important contributor to the development and maintenance
of alcohol dependence (Tiffany and Conklin, 2000). Craving has
been described as a powerful urge to drink or as intense thoughts
about alcohol, and The International Classiﬁcation of Diseases (ICD–
10) includes craving as an optional diagnostic criterion for addiction
to alcohol or other drugs. Both the World Health Organization and
the American Psychiatric Association deﬁne the term as a strong de-
sire or sense of compulsion to take the drug (APA, 1994; WHO,
1992).
Acute alcohol administration results in a variety of effects and
when sensitive instruments are used, a clear sense of euphoria occurs
(Lukas and Mendelson, 1988; Lukas et al., 1986a,b, 1989, 1990).
When a behavior is reinforced or the individual has a positive experi-
ence, it leads to an increased incidence of that behavior (in the case of
Fig. 6. Axial slices depicting changes in BOLD activation. Color-coding identiﬁes regions where the response to alcohol odors was more attenuated in the XR-NTX-treated group
compared to the placebo-treated group, second scan vs. ﬁrst scan (red corresponds to z = 2.3, yellow to z = 4.2).
183S.E. Lukas et al. / NeuroImage 78 (2013) 176–185alcohol—drinking) and the cycle continues (Singleton and Gorelick,
1998). The rewarding effects of alcohol are thought to be mediated
via release of endogenous opioids that then facilitates mesolimbic do-
pamine activity (Gianoulakis et al., 1996). As an opiate receptor an-
tagonist, naltrexone would block this response and has actually
been shown to reduce alcohol-induced increased dopamine activity
in nucleus accumbens (Benjamin et al., 1993). Naltrexone alsoFig. 7. Axial slices depicting changes in BOLD activation. Color-coding identiﬁes regions whe
group compared to the placebo-treated group, second scan vs. ﬁrst scan (red corresponds tappears to dampen alcohol-induced stimulation (Drobes et al.,
2004) and decreases subjective reports of “liking” (McCaul et al.,
2000).
The process of craving is accelerated by the presence of objects, en-
vironments, or emotions that have been previously associated with al-
cohol consumption as they can produce a response that is as powerful
as alcohol itself. Such stimuli/cues may include the sight of a bar, liquorre the response to alcohol-related pictures was more attenuated in the XR-NTX-treated
o z = 2.3, yellow to z = 4.4).
184 S.E. Lukas et al. / NeuroImage 78 (2013) 176–185store, or beverage advertisement; the company of friends who drink; or
exposure to alcohol itself (Heinz et al., 2002). An abstinent alcoholic ex-
posed to appropriate cues will experience a conscious urge, or craving,
for alcohol (Drummond, 2001). It has been suggested that cue-elicited
craving during or after treatment can trigger conscious coping strate-
gies aimed at maintaining abstinence, and the success of coping de-
pends on a drinker's conﬁdence in their ability to resist the urge to
drink (Anton, 1999). It is important to note that craving is only one of
the several factors necessary to induce relapse (Rohsenow and Monti,
1999), but can be a powerful element. Naltrexone reduces the urge to
drink (Monti et al., 2001; Ray and Hutchison, 2007) and the present
study provides some evidence that this is mediated by reducing BOLD
activation in brain regions thatmediate self-awareness, cognition, emo-
tion and reward.
Alcohol consumption may initiate the process of reinforcement by
activating brain reward structures located in the limbic system and pri-
marily consisting of the hypothalamus, amygdala, hippocampus, septal
nuclei, anterior cingulate nucleus, nucleus accumbens, and ventral teg-
mental area (Carlezon and Thomas, 2009; Childress et al., 1999; Koob
and Nestler, 1997). The reward center is linked to other brain areas in-
volved in aspects of emotion, learning, and memory (Kelley, 2004). In-
teractions among these sites could account for the processes by which
1) emotion-laden memories of past positive drinking experiences be-
come associated with cues, and 2) exposure to such cues can activate
the reward center in the absence of alcohol, potentially leading to crav-
ing during abstinence. These processes are unconscious. However, the
reward center also communicates with brain areas that appear to un-
derlie higher intellectual (i.e., cognitive) functions such as judgment
and decision-making. Because of this, heavy drinking may ultimately
impair conscious processes that support the ability to cope with drink-
ing urges (Anton, 1999). The fact that the reductions in BOLD signal
strength to olfactory cues occurred in numerous cortical regions offers
support for this notion and that the concept of craving cannot be
thought of simply affecting basic reward processes.
In the present study, we found that alcohol-related visual and ol-
factory cues elicited signiﬁcant increases in orbital and cingulate
gyri, inferior frontal and middle frontal gyri and that these patterns
of brain activation were signiﬁcantly attenuated in XR-NTX-treated
individuals. In order to measure this, alcohol-related visual and ol-
factory cues were presented to recently detoxiﬁed individuals
while they received an fMRI scan. The alcohol cues produced the
expected increased activation in speciﬁc brain regions. The subjects
were randomized to receive either XR-NTX or placebo, given as a
single i.m. injection. Two weeks later, the fMRI assessment was re-
peated along with the cue exposure paradigm. Those who had
been treated with XR-NTX experienced a marked alterations in
cue-induced brain activation in regions of the brain that are typical-
ly associated with sensory, cognitive, emotional, learning/memory
and reward. Self-reports of craving for alcohol were also reduced
during the 28-min session, but there was no overall signiﬁcant
effect on craving and therefore the effects on craving during the
scanning procedure were modest. Thus, XR-NTX may alter the sa-
lience of both olfactory and visual cues. To the extent that cue reac-
tivity and cue-induced craving play a role in relapse to alcohol use,
reductions in the brain's reaction to these cues may interrupt the
processes that precede a “slip” and relapse, thus contributing to the
ability of XR-NTX to maintain abstinence. The ﬁnding that brain activa-
tion patterns were affected in the absence of an effect on desire to
“want” alcohol at ﬁrst seems counter-intuitive. However, it is important
to recognize that one of the major weaknesses of the measure that we
used to record their desire for alcohol was that it was one-dimensional.
It has been demonstrated that drug and alcohol craving is a multifaceted
behavior (Potgieter et al., 1999; Singleton and Gorelick, 1998), and while
the simplicity of the VAS used in the magnet certainly helped track a po-
tentially transient subjective state, it came at the expense of obtaining a
more multidimensional assessment of desire or craving for alcohol.Nevertheless, it is well known that drinking in an outpatient setting can
be reduced while at the same time changes in craving are not detected.
It is important to note that these changes in BOLD signal activation
were noted after only two weeks of XR-NTX treatment. All participants
received the same amount of supportive therapy including weekly 1 h
counseling sessions. Thus, the speed with which these brain changes
occur suggest that naltrexone has a more immediate effect on brain
function. This change in brain function is consistent with the relatively
rapid appearance of clinical efﬁcacy of even a few days after treatment
has begun (Ciraulo et al., 2008). Thus, the positive temporal relationship
between changes in cue reactivity and clinical efﬁcacy suggests that
changes in brain reactivity could very well be involved in naltrexone's
ability to curb alcohol drinking.
The present study has a few limitations that need to be considered
when interpreting the results. While the sample size is reasonable for
an imaging study that utilizes stimuli presentation, it was not powered
for a treatment study. Moreover, assessing the efﬁcacy of XR-NTX in re-
ducing alcohol consumption in an outpatient study cannot be performed
after only one month of treatment, but again this was not an aim of the
study. The study was also not powered to detect male vs. female differ-
ences in cue reactivity even though it is possible that women may re-
spond differently to alcohol- (Seo et al., 2011) and smoking- (Saladin
et al., 2012) related cues. It is generally believed that individualized
cues aremore salient to individuals andwhile we presented participants
with the odor of their preferred alcoholic beverage, the picture set was
standardized across all participants. We felt that providing individual vi-
sual stimuli would make the interpretation of the data too complicated.
Cue reactivity is a recognized predictor of relapse of drug and alcohol
use (Cooney et al., 1997; Garland et al., 2012). The areas affected by the
picture- and odor-related cues in the present study are signiﬁcant be-
cause they engage a wide range of neuronal resources that process ex-
ternal stimuli and formulate appropriate emotional responses that not
only contributes to the craving response, but also tap into reward pro-
cesses. As enhanced craving and high reward after drinking contribute
to relapse, the degree to which XR-NTX reduces the saliency of these
cues may very well be responsible for its effect on interrupting the pro-
cesses that precede a “slip” and furthermore should also reduce the like-
lihood that a slip (i.e., single drink), should it occur, would turn into
relapsed drinking.Acknowledgments
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